News
FATE
2.530
+0.40%
0.010
Fate Therapeutics Says Four Abstracts From Off-The-Shelf CAR T-Cell Programs Selected For Presentation At ACR Convergence 2026
Benzinga · 4d ago
Weekly Report: what happened at FATE last week (0907-0911)?
Weekly Report · 6d ago
Fate Therapeutics announces clinical data from FT819 study
TipRanks · 09/09 11:45
Fate Therapeutics To Present Clinical Data From Off-The-Shelf Anti-CD19 CAR T-Cell Product Candidate FT819, And Pre-Clinical Data From Anti-CD19 And CD38 CAR T-Cell Product Candidate FT839 At CCR – West Meeting
Benzinga · 09/09 11:08
Weekly Report: what happened at FATE last week (0831-0904)?
Weekly Report · 09/07 10:11
Fate Therapeutics: RECLAIM-LN Underway, Additional Clinical Updates Ahead
Seeking Alpha · 09/02 16:55
Fate Therapeutics Expands Into Autoimmune Disease With New FT839 Trial
TipRanks · 09/02 16:31
Fate Therapeutics Advances FT819 Cell Therapy Into Phase 2 Lupus Nephritis Trial
TipRanks · 09/02 16:30
Weekly Report: what happened at FATE last week (0824-0828)?
Weekly Report · 08/31 10:18
Weekly Report: what happened at FATE last week (0817-0821)?
Weekly Report · 08/24 10:19
Fate Therapeutics (FATE) Gets a Buy from Mizuho Securities
TipRanks · 08/17 16:25
Weekly Report: what happened at FATE last week (0810-0814)?
Weekly Report · 08/17 10:20
Fate Therapeutics reports Q2 EPS (25c), consensus (26c)
TipRanks · 08/17 07:43
Fate Therapeutics price target raised to $3.50 from $2.50 at Wells Fargo
TipRanks · 08/16 13:49
Fate Therapeutics intiates first patient in RECLAIM-LN trial
TipRanks · 08/16 13:40
Fate Therapeutics Price Target Raised to $8.00/Share From $6.00 by Piper Sandler
Dow Jones · 08/14 16:42
Piper Sandler Reiterates Overweight on Fate Therapeutics, Raises Price Target to $8
Benzinga · 08/14 16:31
Fate Therapeutics Advances FT819 Doses First Patient In Lupus Nephritis Trial
NASDAQ · 08/14 15:27
Fate Therapeutics Is Maintained at Equal-Weight by Wells Fargo
Dow Jones · 08/14 15:09
Fate Therapeutics Price Target Raised to $3.50/Share From $2.50 by Wells Fargo
Dow Jones · 08/14 15:09
More
Webull provides a variety of real-time FATE stock news. You can receive the latest news about Fate Therapeutic through multiple platforms. This information may help you make smarter investment decisions.
About FATE
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing off-the-shelf, multiplexed-engineered, induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. The Company's pipeline includes iPSC-derived, chimeric antigen receptor (CAR)-targeted T-cell and NK cell product candidates. The iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. The Company's product candidates under development include FT819, FT522, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT825 is its first iPSC-derived CAR T-cell product candidate for the treatment of solid tumors being developed in collaboration with Ono Pharmaceutical. FT836 is the Company's multiplexed-engineered CAR T-cell product candidate targeting MHC proteins MICA and MICB.